PepGen Inc.

PepGen Inc. (PEPG) priced its initial public offering on May 9, 2022 at $12.00 per share, below its $13.00–$15.00 range, raising $108M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $268.7M. BofA Securities was lead-left underwriter, joined by Stifel and Wedbush. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Its Enhanced Delivery Oligonucleotide platform uses cell-penetrating peptides to improve uptake and activity of conjugated oligonucleotides.

Status

IPO

Ticker

PEPG

Exchange

Nasdaq Global Select

Priced

May 9, 2022

IPO price

$12.00

Price range

$13.00–$15.00

Raised

$108M

Market cap at IPO price

$268.7M

First filed

Apr 15, 2022

Underwriters

BofA Securities, Stifel and Wedbush

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.